Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?

Tally Is Behind Recent Years

 
• By Andrew McConaghie
  
Pfizer capsules
Pfizer has invested some of its COVID-19 windfall in M&A, most notably the $11.6bn buyout of Biohaven. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business